Skip to content

Preoperative Cognitive Therapy for Improving Health Outcomes After TKA in High-risk Catastrophizing Subjects

Preoperative Cognitive Therapy for Improving Health Outcomes After Total Knee Replacement in High-risk Catastrophizing Subjects

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01772329
Acronym
CT_TKA
Enrollment
160
Registered
2013-01-21
Start date
2013-01-31
Completion date
2020-10-31
Last updated
2022-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catastrophization

Brief summary

The investigators propose a randomized controlled trial to evaluate the effects of treatment intended to reduce pain catastrophizing among patients reporting high pain catastrophizing prior to total knee replacement(TKR), total hip replacement(THR), or shoulder surgery in an effort to thereby reduce the incidence of persistent post-surgical pain (PPP) and enhance physical function at 3-months post-surgery. Preemptive treatment aimed at a known predictor of PPP following total knee replacement is highly innovative and have potentially high impact for public health. Cognitive therapy is a well-tolerated modality among chronic pain patients with few if any side effects. Cognitive therapy (CT) represents an inexpensive method that could greatly reduce suffering and costly post-surgical pain management for high risk TKR patients.

Detailed description

Aim 1 is to determine which CT protocol is most effective in reducing Pain Catastrophizing Scale (PCS) and Coping Strategies Questionnaire Catastrophizing Subscale (CSQ-CAT) scores in high-risk TKR candidates. CT will consist of four-to-eight weekly 1-hr individual cognitive therapy sessions prior to surgery. Aim 2 is to compare the most efficient treatment from Aim 1 with a control group to evaluate pain relief at 3 months.

Interventions

OTHERRoutine Care

Routine Care. No Cognitive Therapy Intervention

OTHERCognitive Therapy

CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.

Sponsors

Pfizer
CollaboratorINDUSTRY
Rush University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Intervention model description

n=80 Subjects for Aim 1 and another n=80 Subjects for Aim 2

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

1. undergoing standard primary TKR; THR or Shoulder Surgery 2. 18- 85 yrs of age; 3. Surgical joint is the primary source of patient's pain; 4. Patient agrees to preoperative visits and treatment, follow-up visits and treatment, and to comply with the assessment tests; 5. Patient consents to standard anesthetic and analgesic protocol, with medical care as deemed necessary by the anesthesiologist, and has no contraindications. 6. Patient has been diagnosed with osteoarthritis.

Exclusion criteria

1. Currently using antidepressant medication or undergoing cognitive therapy; 2. chronic opioid use ≥ 10 mg/day of morphine equivalents within one wk prior to the surgery, and duration of use \> 4 wks; 3. history of opioid abuse; 4. inability to understand and communicate with the investigators to complete the study related questionnaires 5. patient is planning to undergo another elective joint procedure during the 6-mo period of participation; 6. any co-morbidity which results in severe systemic disease limiting function {as defined by the American Society of Anesthesiology (ASA) physical status classification \> 3}.

Design outcomes

Primary

MeasureTime frameDescription
(Aim 1) Pain Catastrophizing Scale (PCS)4 or 8 weeks after start of treatmentPain Catastrophizing Scale - Min=0, Max=52, Higher score = more catastrophizing so lower scores are preferable.
(Aim 2) Proportion of patients with pain relief3 monthProportion of patients w a 3 month decrease in WOMAC pain subscale \<= 4. (WOMAC Osteoarthritis Index)

Secondary

MeasureTime frameDescription
Patient Health Questionnaire (PHQ-8)4 and 8 weeks after start of treatmentPatient Health Questionnaire (PHQ-8): The eight-item Patient Health Questionnaire depression scale (PHQ-8) is established as a valid diagnostic and severity measure for depressive disorders
Generalized anxiety disorder (GAD-7)4 and 8 weeks after start of treatmentGeneralized anxiety disorder (GAD-7): The seven-item Generalized Anxiety Disorder Scale (GAD-7) is a practical self-report anxiety questionnaire.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026